Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8555060rdf:typepubmed:Citationlld:pubmed
pubmed-article:8555060lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:8555060lifeskim:mentionsumls-concept:C0010654lld:lifeskim
pubmed-article:8555060lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:8555060lifeskim:mentionsumls-concept:C0369765lld:lifeskim
pubmed-article:8555060lifeskim:mentionsumls-concept:C0347532lld:lifeskim
pubmed-article:8555060lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:8555060pubmed:issue3lld:pubmed
pubmed-article:8555060pubmed:dateCreated1996-2-23lld:pubmed
pubmed-article:8555060pubmed:abstractTextThe interaction of rare Hb variants with beta(0)-thalassaemia results in a quasihomozygous state where the erythrocytes contain the variant as the only major adult Hb component. Such a situation is a unique model that enables functional studies even in the case of a neutral variant that could not be isolated from Hb A. We report here an unusual patient carrying Hb Arta, a novel Hb variant [beta 45 (CD4) Phe-->Cys], in trans with beta(0)-thalassaemia gene (beta(0) 39). The aminoacid substitution at the critical CD corner of this Hb molecular renders the molecule unstable. In addition, haem is displaced in a position that favours the deoxy (T) conformation of the variant, but less than in Hb Cheverly [beta 45 (CD4) Phe-->Ser], and results in a p50 of 43 mmHg (pH 7.4, 37 degrees C) in the red cells with preservation of cooperativity. Solution studies of the almost pure Hb Arta show a 50% decrease in oxygen affinity and normal cooperativity; the Bohr effect and the interaction with organic phosphates are similar to those of Hb A. Hb Arta retains both normal homo- and heterotropic effects allowing a well-preserved oxygen transport in vivo despite a mild anaemia.lld:pubmed
pubmed-article:8555060pubmed:languageenglld:pubmed
pubmed-article:8555060pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8555060pubmed:citationSubsetIMlld:pubmed
pubmed-article:8555060pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8555060pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8555060pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8555060pubmed:statusMEDLINElld:pubmed
pubmed-article:8555060pubmed:monthNovlld:pubmed
pubmed-article:8555060pubmed:issn0007-1048lld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:PoyartCClld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:WajcmanHHlld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:MardenMMlld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:VoskaridouEElld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:Vassilopoulou...lld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:KisterJJlld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:GriffonNNlld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:Papassotiriou...lld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:Stamoulakatou...lld:pubmed
pubmed-article:8555060pubmed:authorpubmed-author:PremetisEElld:pubmed
pubmed-article:8555060pubmed:issnTypePrintlld:pubmed
pubmed-article:8555060pubmed:volume91lld:pubmed
pubmed-article:8555060pubmed:ownerNLMlld:pubmed
pubmed-article:8555060pubmed:authorsCompleteYlld:pubmed
pubmed-article:8555060pubmed:pagination595-601lld:pubmed
pubmed-article:8555060pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:meshHeadingpubmed-meshheading:8555060-...lld:pubmed
pubmed-article:8555060pubmed:year1995lld:pubmed
pubmed-article:8555060pubmed:articleTitleHb Arta [beta 45 (CD4) Phe-->Cys]: a new unstable haemoglobin with reduced oxygen affinity in trans with beta-thalassaemia.lld:pubmed
pubmed-article:8555060pubmed:affiliationFirst Department of Medicine, Laikon Hospital, Athens, Greece.lld:pubmed
pubmed-article:8555060pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8555060pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:8555060pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8555060lld:pubmed